Finally, in vivo efficacy of the more effective antibody was confirmed in three studies in two tauopathy mouse models that showed its acute tau clearance, improvement in neuronal function, and reduced microglial activation, as well as its clearance of insoluble tau following chronic treatment. This evidence concerns the gene MAPT and tauopathy.